Share

March 14, 2017; 88 (11) Article

Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease

Nicolai Franzmeier, Marco Duering, Michael Weiner, Martin Dichgans, Michael Ewers, For the Alzheimer's Disease Neuroimaging Initiative (ADNI)
First published February 10, 2017, DOI: https://doi.org/10.1212/WNL.0000000000003711
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
350

Share

Article Information

vol. 88 no. 11 1054-1061
DOI: 
https://doi.org/10.1212/WNL.0000000000003711
PubMed: 
28188306
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received May 19, 2016
  • Accepted in final form December 20, 2016
  • First Published February 10, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Nicolai Franzmeier, MSc,
    2. Marco Duering, MD,
    3. Michael Weiner, MD,
    4. Martin Dichgans, MD,
    5. Michael Ewers, PhD;
    6. For the Alzheimer's Disease Neuroimaging Initiative (ADNI)
  1. Nicolai Franzmeier, MSc,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Alzheimer's Association, Travel Fellowship

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Marco Duering, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel expenses for lectures from Kenes International, European Stroke Conference. Speaker honoraria from Bayer Vital GmbH.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) German Center for Neurodegenerative Diseases (DZNE), VaD/MixD, PI, 2011-2014 (2) LMU FoeFoLe, 808, PI, 2013-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Vascular Dementia Research Foundation, (2) Else Kr?ner-Fresenius- Stiftung, 2014-A200, PI, 2015-2017

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Michael Weiner, MD,
    4. Scientific Advisory Boards:

    1. He has served on the Scientific Advisory Boards for Pfizer, Alzheon, Inc., Eli Lilly, Dolby Ventures, and ADNI. He served on the Editorial Boards for Alzheimer?s & Dementia and MRI

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. The following entities have provided funding for academic travel; Pfizer, Kenes, Intl., UCSD; ADCS, ATRI, Merck, University Center Hospital, Toulouse, Araclon, AC Immune, Nutricia,Eli Lilly, New York Academy of Sciences (NYAS), The Alzheimer?s Association, Alzheimer?s Drug Discovery Foundation (ADDF), Tokyo University, Kyoto University, Weill-Cornell University, Rockafeller University, Memorial Sloan-Kettering Cancer Center, and Biogen Idec.

    Editorial Boards:

    1. Served on the Editorial Boards for Alzheimer?s & Dementia and MRI.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. University of California, San Francisco; San Francisco VA Medical Center (WOC employment)

    Consultancies:

    1. He has provided consulting and/or acted as a speaker/lecturer to Synarc, Pfizer, Janssen, Accera Pharmaceuticals, Alzheimer?s Drug Discovery Foundation (ADDF), Avid Radiopharmaceuticals, Araclon, Merck, The Scienomics Group (TSG), AVOS Consulting, INC Research), Biogen Idec, BioClinica, Eli Lilly, The Alzheimer?s Association, Howard University, Guidepoint, Alzheon, and Genentech.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Weiner receives support for his work from the following grants; 2U01AG024904 (NIH/NIA), W81XWH-13-1- 0259 (DOD), W81XWH-12-2-0012 (DOD), R01 AG010897 (NIA/NIH), P01 AG19724 (NIH/NIA), R01A G038791 (NIA/NIH), ADNI 2-12-233036 (Alzheimer?s Association), R01 MH098062- 01 (NIH/NIMH), 1I01CX000798-01A2 (Veterans Administration), W81XWH-14-1-0462 (DOD), W81XWH-09-2-0044 (DOD), 12-12004 (CA Department of Public Health), 5U19AG010482-23 (NIH/NIA), P50 AG23501 (NIH/NIA), W81XWH- 15-2-0070 (USA Med Research Ac Activity), 20150802 (Alzheimer's Drug Discovery Foundation), 444951-54249 (Siemens), and the Veterans Administration, and support for the Brain Health Registry from: The Rosenberg Alzheimer?s Project (David Rosenberg), The Ray and Dagmar Dolby Family Fund, Connie and Kevin Shanahan, Global Alzheimer's Platform Foundation, Inc., PCORI, General Electric, Monell Chemical Senses Center, The Alzheimer?s Association, Biogen Idec,The Stroke Foundation, Johnson & Johnson, Cogstate, and The Drew Foundation (Ellen Drew).

    Research Support, Government Entities:

    1. NIH, DOD, VA

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. He holds stock options with Alzheon, Inc. and Alzeca

    Stock/Stock Options, Medical Equipment & Materials:

    1. He holds stock options with Alzheon, Inc.

    Legal Proceedings:

    1. NONE

  4. Martin Dichgans, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer Vital, (2) Boehringer Ingelheim, (3) Bristol- Meyer Squibb, (4) Daiichi Sankyo

    Editorial Boards:

    1. (1) Stroke the International Journal of Stroke, editor, (2) Cerebrovascular diseases, editorial board member, (3) Journal of Neurochemistry, editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Bayer Vital, (2) Boehringer Ingelheim, (3) Bristol- Meyer Squibb, (4) Daiichi Sankyo

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Wellcometrust, 03/08 following, (2) European Union (EU FP 7), investigator, 10/13-09/16, (3) German Federal Ministry of Education and Research (BMBF), investigator, 12/13-11/16, (4) European Union (EU FP 6), investigator, 03/12-02/15

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Vascular Dementia Research Foundation, (2) Corona Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Michael Ewers, PhD;
    6. Scientific Advisory Boards:

    1. Non-profit: Member of the scientific advisory board for the European Prevention Alzheimer's Dementia Consortium (EPAD). EPAD includes universities, pharmaceutical companies and patient organizations. I reveive no royalties for my advisory activities.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Received compensation of expenses for traveling to conferences from the Alzheimer's Association and International College of Geriatric Psychoneuropharmacology.

    Editorial Boards:

    1. Senior Editor of Alzheimer's & Dementia.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. For the Alzheimer's Disease Neuroimaging Initiative (ADNI)
  1. From the Institute for Stroke and Dementia Research (N.F., M. Duering, M. Dichgans, M.E.), Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany; University of California at San Francisco (M.W.); Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (M. Dichgans), Munich, Germany.
  1. Correspondence to Dr. Ewers: Michael.Weiner{at}ucsf.edu
View Full Text

Article usage

Article usage: February 2017 to February 2023

AbstractFullPdfSource
Feb 20171554035Highwire
Mar 201718611353Highwire
Apr 2017475814Highwire
May 201741148Highwire
Jun 201717958Highwire
Jul 201711076Highwire
Aug 20177834Highwire
Sep 20179456Highwire
Oct 20174766Highwire
Nov 20176285Highwire
Dec 20179142Highwire
Jan 201811552Highwire
Feb 20186957Highwire
Mar 20187015Highwire
Apr 20187217Highwire
Apr 2018141920pmc
May 20185856Highwire
Jun 20187012Highwire
Jun 201871620pmc
Jul 20185415Highwire
Aug 20183722Highwire
Aug 2018111818pmc
Sep 20189565Highwire
Oct 201862512Highwire
Nov 20187022Highwire
Dec 20185135Highwire
Jan 20193043Highwire
Feb 20194701Highwire
Mar 20194805Highwire
Apr 20193112Highwire
May 20196623Highwire
Jun 20197562Highwire
Jul 20194244Highwire
Aug 20194334Highwire
Sep 20191934Highwire
Oct 20193612Highwire
Nov 20194010Highwire
Dec 20192610Highwire
Jan 20203253Highwire
Feb 20204121Highwire
Mar 20204213Highwire
Apr 20206601Highwire
May 20207500Highwire
Jun 20204600Highwire
Jul 20204521Highwire
Aug 20204611Highwire
Sep 20203212Highwire
Oct 20208600Highwire
Nov 20206831Highwire
Dec 20206112Highwire
Jan 20215743Highwire
Feb 20215700Highwire
Mar 20214511Highwire
Apr 20216521Highwire
May 20215122Highwire
Jun 20215824Highwire
Jul 20217533Highwire
Aug 20216723Highwire
Sep 20216140Highwire
Oct 20217712Highwire
Nov 20219822Highwire
Dec 20218701Highwire
Jan 20226611Highwire
Feb 20227832Highwire
Mar 20228234Highwire
Apr 202210573Highwire
May 20229331Highwire
Jun 20227300Highwire
Jul 20226701Highwire
Aug 20225322Highwire
Sep 20229501Highwire
Oct 20226000Highwire
Nov 20225211Highwire
Dec 20226600Highwire
Jan 20238120Highwire
Feb 20239622Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles